A20 | GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture | On-demand oral abstract session | Eliminating and silencing latency |
A5 | Proteomic evidence of vesatolimod-induced enhancement of 'cross-talk' between innate and adaptive immune cells in HIV controllers on ART | On-demand oral abstract session | Innate immunity |
A9 | The circadian clock machinery regulates HIV transcription in CD4+ T cells | On-demand oral abstract session | Systemic immune activation and inflammation |
A23 | RNA-directed gene therapy protects CD4+ T cells during HIV challenge and delays virus rebound post-ART in humanized mice | On-demand oral abstract session | Gene therapy |
A21 | The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaques | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
A25 | Early antiretroviral therapy favors post-treatment SIV control, which is associated with enhanced CD8+ T-cell antiviral activity against rebounding virus ' the pVISCONTI study | On-demand oral abstract session | HIV-1 controllers (including post-treatment controllers) and long-term non-progressors |
A19 | Evaluation of HIV-1 reservoir size and broadly neutralizing antibody (bNAb) susceptibility in individuals who initiated ART during acute and chronic infection | On-demand oral abstract session | Characterizing HIV/SIV reservoirs and rebounding virus |
B80 | Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV | On-demand oral abstract session | Immune responses against SARS-CoV2 in PLWHIV |
B30 | Rising substance use linked to STI and HCV in Thai MSM after acute HIV infection | On-demand oral abstract session | Substance abuse (including opioid use disorder) |
B13 | High HCV cure rates in C-FREE, first community-based study offering testing and treatment of viral hepatitis and HIV among people who use drugs and their partners in Thailand | On-demand oral abstract session | Viral hepatitis C |